Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Vaccines|July 29, 2023
Coronavirus Disease 2019 (COVID-19) Reinfection Rates in Malawi: A Possible Tool to Guide Vaccine Prioritisation and Immunisation PoliciesMaster R O Chisale, Frank Watson Sinyiza, Paul Uchizi Kaseka, et al.
Patterns (New York, N.Y.)|September 5, 2024
Concepts and applications of digital twins in healthcare and medicineKang Zhang, Hong-Yu Zhou, Daniel T Baptista-Hon, et al.
Journal of Medical Internet Research|July 16, 2026
Describing a National Chatbot Deployed by the Ministry of Health in Malawi During the COVID-19 Pandemic: Retrospective Data AnalysisIsaach Ndemera, Yu-Ting Sunny Hsieh, Kingston Chirwa, et al.
Advances in Rheumatology (London, England)|December 19, 2024
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitisAtul Deodhar, Servet Akar, Jeffrey R Curtis, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
BMJ Open Gastroenterology|January 8, 2025
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitisSéverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 2007
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptinTesfaye Biftu, Giovanna Scapin, Suresh Singh, et al.
JMIR Public Health and Surveillance|January 26, 2026
Establishing One Health Surveillance Platform for Electronic Integrated Disease Surveillance and Response in Malawi: Action Design Research StudyTsung-Shu Joseph Wu, Matthew Vundu Mvula, Edward Kada Koma Chado, et al.
Rheumatology and Therapy|June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension StudyPeter Nash, Laura C Coates, Alan J Kivitz, et al.
Annals of the Rheumatic Diseases|September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL SurveillanceChristina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
Pageof 13